We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Patients on a shorter dosing regimen in Gilead’s phase 3 remdesivir trial saw clinical improvements similar to those on the 10-day treatment schedule, the drugmaker announced Wednesday, offering hope of a COVID-19 treatment. Read More
Merck said its oncology blockbuster Keytruda (pembrolizumab) is just as safe and effective in a dose of 400 mg every six weeks for first-line treatment of melanoma as at the approved dosing regimen of 200mg every three-weeks. Read More
Remdesivir should be part of the “first wave” of efforts to expedite COVID-19 treatments and vaccines, the members of Scientists to Stop COVID-19 said in a plan submitted to the White House. Read More
Challenge studies for COVID-19 vaccines are “incomprehensible” as long as there are safer alternatives, Generex CEO Joe Moscato said yesterday, responding to a letter from lawmakers last week on the subject. Read More